QMS Medical Allied Services Limited (QMSMEDI)
Investor Presentation
Press Release - Q1FY27
- Consolidated revenue Rs 56.9 Cr +22% y-y; EBITDA Rs 8.3 Cr +27% y-y; PAT Rs 4 Cr +25% y-y
- Products business grew on expanded distribution and Q-Devices portfolio
- Services business growth driven by pharma partnerships and Patient Support Programs
- Acquired 76% stake in Saarathi Healthcare; full acquisition expected by end Q2FY27
- Conducted 11,497 B2B health camps in Q1FY27
- Focus on scaling Patient Support Programs, expanding Q-Devices and Point-of-Care offerings
- FY26 revenue Rs 173 Cr; EBITDA margin steady at 15.0%
- Strong digital platform with 1M+ patients tracked and 350,000+ healthcare professionals engaged
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 QMSMEDI — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add QMSMEDI to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on QMS Medical Allied Services Limited
Important.
The summary above is generated automatically from QMS Medical Allied Services Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.